<DOC>
	<DOCNO>NCT00706316</DOCNO>
	<brief_summary>Nasopharyngeal cancer ( NPC ) cancer start back nose . Without distant spread , NPC sensitive radiotherapy chemotherapy ; however , NPC relapse spread organ , treatment option limit . This grant propose evaluate safety tolerability novel treatment patient NPC either relapse spread distant organ . Epstein-Barr Virus ( EBV ) know play role development NPC , study show NPC tumor cell express protein relate EBV . Some protein trigger response immune system , specifically activation cytotoxic T lymphocytes ( CTLs ) , type immune cell might exert anti-tumor effect . In project , take blood NPC patient , generate CTLs target EBV , re-infuse back patient attempt achieve anti-tumor activity . Patients also receive antibody call CD45 Mab prior CTL infusion order allow good expansion infuse CTLs patient .</brief_summary>
	<brief_title>Administration Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes Metastatic EBV-Positive Nasopharygneal Cancer</brief_title>
	<detailed_description>Nasopharyngeal cancer ( NPC ) cancer start back nose . Without distant spread , NPC sensitive radiotherapy chemotherapy . However , treatment cancer lead later complication , include cancer , NPC relapse spread organ , treatment option limit . This grant propose evaluate safety tolerability novel treatment patient NPC either relapse spread distant organ . Epstein-Barr Virus ( EBV ) know play role development NPC individual , especially compromise immune system . Studies show NPC tumor cell express protein relate EBV . Some protein trigger response immune system , specifically activation cytotoxic T lymphocytes ( CTLs ) , type immune cell might exert anti-tumor effect . In project , take blood NPC patient , generate CTLs target EBV , re-infuse back patient attempt achieve anti-tumor activity . Patients also receive antibody call CD45 Mab prior CTL infusion order allow good expansion infuse CTLs patient .</detailed_description>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>Any patient EBV positive NPC , recurrent and/or metastatic disease Patients life expectancy &gt; 3 month . Patients ECOG performance status 0 , 1 2 No severe intercurrent infection . Patients able give inform consent . Patients : bilirubin &lt; 2x normal , SGOT ( AST ) SGPT ( ALT ) &lt; 3x normal , Hgb &gt; 80 g/L , absolute neutrophil count ( ANC ) &gt; 1.5 x 109/L , platelet &gt; 100 x 109/L . Patients creatinine &lt; 2x normal age Patients chemotherapy investigational therapy least 4 week prior entry study . Patients complete prior radiation therapy least 3 week prior entry study . Exception may make , however , lowdose , nonmyelosuppressive radiotherapy , must discuss Principal Investigator ( ) . All patient must measurable disease , minimum indicator lesion size follow : CT scan &gt; 2 cm ( &gt; 1 cm spiral CT scan use ) Ultrasound &gt; 2 cm Chest xray &gt; 2 cm Physical exam &gt; 1 cm ( skin lesion , node , soft tissue mass ) Patients life expectancy &lt; 3 month . Patients ECOG performance status &gt; 2 . Patients severe intercurrent infection . Patients unable unwilling give inform consent . Patients bilirubin &gt; 2x normal . SGOT ( AST ) SGPT ( ALT ) &gt; 3x normal . Patients creatinine &gt; 2x normal age Patients Hgb &lt; 80 g/L , absolute neutrophil count ( ANC ) &lt; 1.5 x 109/L , platelet &lt; 100 x 109/L . Due unknown effect therapy fetus , pregnant woman exclude research . Lactating woman exclude study . Patients partner must use effective birth control method study 6 month . Effective birth control method : total abstinence , oral contraceptive , intrauterine device , contraceptive implant skin contraceptive injection . If one method use , contraceptive foam condom allow . The male partner use condom .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Nasopharygneal Cancer</keyword>
	<keyword>Epstein Barr Virus</keyword>
	<keyword>( EBV ) -Specific Cytotoxic T-Lymphocytes</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Metastatic</keyword>
	<keyword>EBV-Positive Nasopharygneal Cancer</keyword>
</DOC>